Business
AZN new Head of Investor Relations Joris Silon
AstraZeneca has appointed Joris Silon as its new Head of Investor Relations, effective March 1, 2026, succeeding Andy Barnett. Silon, who will be based in Cambridge, UK, previously served as Country President of AstraZeneca US, where he drove significant growth in the company's largest market. His extensive pharmaceutical experience spans leadership roles across Asia, Europe, and the US since joining the company in 2000. The Chief Financial Officer expressed confidence in Silon's ability to lead the Investor Relations team through the company's next growth phase and thanked Barnett for his four years of leadership. Disclaimer*
About this update from Astrazeneca Plc
[{"type":"text","content":"\n\n \n8 January 2026\nAstraZeneca appoints Joris Silon as Head of Investor Relations \nAstraZeneca's new head of Investor Relations, Joris Silon, succeeds Andy Barnett on 1 March 2026, and will be based in Cambridge, UK.\n \nJoris is moving from his role as the country president of AstraZeneca US where he led and delivered significant growth for the Company in its largest market. Joris brings extensive pharmaceutical experience, having joined the Company in 2000 and has held leadership positions in Asia, Europe and the US.\n \nAradhana Sarin, Chief Financial Officer, said \"I am delighted that such a highly experienced and talented leader as Joris will lead our Investor Relations team through our next wave of growth. I would also like to thank Andy Barnett for his remarkable leadership of our Investor Relations team over the past 4 years and wish him the best of luck as he transitions to an important new role within the Company.\"\n \nNotes\n \nAstraZeneca\nAstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.\n \nContacts\nFor details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.\n\n","length":2829,"tagName":"div"}]